| Literature DB >> 27155055 |
Marcelo Comerlato Scotta1, Valentina Coutinho Baldoto Gava Chakr2, Angela de Moura1, Rafaela Garces Becker1, Ana Paula Duarte de Souza1, Marcus Herbert Jones1, Leonardo Araújo Pinto1, Edgar Enrique Sarria3, Paulo Marcio Pitrez1, Renato Tetelbom Stein1, Rita Mattiello4.
Abstract
BACKGROUND: With advent of molecular diagnostic technologies, studies have reported detection of two or more respiratory viruses in about 30% of children with respiratory infections. However, prognostic role of coinfection remains unclear.Entities:
Keywords: Child; Coinfection; Prognosis; Respiratory insufficiency; Respiratory tract infections; Viruses
Mesh:
Year: 2016 PMID: 27155055 PMCID: PMC7185664 DOI: 10.1016/j.jcv.2016.04.019
Source DB: PubMed Journal: J Clin Virol ISSN: 1386-6532 Impact factor: 3.168
Fig. 1Flow diagram of study selection process.
Characteristics of studies included in main analysis.
| First author | Year | Country | Number of patients compared | Prevalence of coinfection (%) | Age | Design | Clinical Syndrome/Comorbitidies (%) | Setting | Viruses tested with biology molecular assays | Comparison | Outcome included |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2013 | South Korea | 187 | 57.2 | <18 y | Prospective | ARI/No | ER | RSV, Flu, PIV, AdV, HRV, hMPV, HCoV, HBoV | HBoV coinfection vs HBoV single infection | LOS | |
| 2011 | USA | 80 | 15 | <9 y | Prospective | LRTI/76.3 | PICU | RSV, Flu, PIV, AdV, HRV, hMPV, EV | Coinfection vs single infection | Death | |
| 2014 | Brazil | 34 | 50 | <2 y | Prospective | LRTI/100 (Preterm) | PW | RSV, Flu, PIV, AdV, HRV, hMPV, HCoV, HBoV | RSV coinfection vs RSV single infection | LOS | |
| 2015 | Canada | 472 | 17.1 | <18 y | Retrospective | ARI/33 | ER, PW, PICU | RSV, Flu, PIV, AdV, HRV, hMPV, HCoV, HBoV, EV | Coinfection vs single infection | NH, NPICU and Death | |
| 2011 | Netherlands | 104 | 41.3 | <2 y | Prospective | Bronchiolitis/19 | ER, PW | RSV, Flu, PIV, AdV, HRV, hMPV, HCoV, HBoV, EV | RSV coinfection vs RSV single infection | NMV | |
| 2008 | Spain | 172 | 86 | <2 y | Prospective | LRTI/15 | PW | RSV, Flu, PIV, AdV, HRV, hMPV, HCoV, EV | Coinfection vs RSV single infection | LOS | |
| 2008 | Spain | 226 | 26.9 | <3 y | Prospective | Pneumonia/4 | ER | RSV, Flu, PIV, AdV, HRV, hMPV, HCoV, HBoV | Coinfection vs single infection | NH | |
| 2013 | Brazil | 337 | 31.4 | <5 y | Retrospective | ARI/16.3 | ER | RSV, Flu, PIV, AdV, HRV, hMPV | RSV + HRV vs RSV | LOS | |
| 2013 | Brazil | 215 | 10.2 | <3 y | Prospective | LRTI/24 | ER | RSV, Flu, PIV, AdV, HRV, hMPV, HCoV, HBoV | RSV + HRV vs. HRV and RSV single infection | LOS and LO2 | |
| 2011 | Vietnam | 222 | 27.2 | <15 y | Prospective | LRTI/Not mentioned | PW, PICU | RSV, Flu, PIV, AdV, HRV, hMPV, HCoV, HBoV, EV | Coinfection vs single infection | LOS, NO2 and NPICU | |
| 2010 | Germany | 303 | 32 | <16 y | Prospective | LRTI/48 | ER | RSV, Flu, PIV, AdV, HRV, hMPV, HCoV, HBoV, EV | RSV coinfection vs RSV, HRV coinfection vs HRV, HBoV coinfection vs HBoV, AdV coinfection vs AdV | LOS, NO2 | |
| 2011 | France | 37 | 37.8 | <2 y | Retrospective | Bhonchiolitis/pneumonia/58 | PICU | RSV, Flu, PIV, AdV, HRV, hMPV, HCoV, HBoV, EV | RSV coinfection vs RSV | NMV | |
| 2013 | Brazil | 70 | 25.7 | <5 y | Prospective | ARI/Not mentioned | ER | RSV, Flu, PIV, AdV, HRV, hMPV, HCoV, HBoV, EV | RSV coinfection vs RSV | LOS, NMV | |
| 2007 | Spain | 52 | 75 | <14 y | Prospective | ARI/21 | ER, PW | RSV, Flu, PIV, AdV, HRV, hMPV, HBoV | HBoV coinfection vs HBoV single infection | LOS, NO2 | |
| 2008 | Italy | 47 | 31.9 | <3 y | Prospective | LRTI/Not mentioned | PW | RSV, Flu, PIV, AdV, HRV, hMPV, HCoV, HBoV, EV | RSV coinfection vs RSV | LOS | |
| 2012 | United Kingdom | 2157 | 6.7 | <5 y | Retrospective | ARI/Not mentioned | OUT, ER, PW | RSV, Flu, PIV, AdV, HRV, hMPV | Flu A (H1N1) and A (H3N2) single infections vs coinfection between both and Flu B, RSV, AdV, HRV (vs (H1N1 only), hMPV (vs H3N2 only) | NH | |
| 2014 | United Kingdom | 6065 | 16.7 | <5 y | Retrospective | ARI/Not mentioned | OUT, ER, PW | RSV, Flu, PIV, AdV, HRV, hMPV | Coinfection vs single infection | NH | |
| 2013 | Cambodja | 551 | 10.8 | <5 y | Prospective | LRTI/2 | PW | RSV, Flu, PIV, AdV, HRV, hMPV, HCoV, HBoV, EV | Coinfection vs single infection | LOS and Death | |
| 2012 | France | 126 | 67.4 | <1 y | Prospective | Bronchiolitis/Not mentioned | PW | RSV, Flu, PIV, AdV, HRV, hMPV, HCoV, HBoV, EV | Coinfection vs single infection | LOS, LO2, NO2 and NPICU | |
| 2013 | Greece | 397 | 42.5 | <14 y | Prospective | ARI/15.2 | ER | RSV, Flu, PIV, AdV, HRV, hMPV, HCoV, HBoV | Coinfection vs single infection | NH | |
| 2011 | Norway | 130 | 10.7 | <16 y | Prospective | ARI/33 | ER | RSV, Flu, PIV, AdV, HRV, hMPV, HCoV, HBoV, EV | RSV + HCoV vs RSV, HCoV OC43 and HCoV NL63 | LOS | |
| 2014 | United Kingdom | 448 | 10.4 | <16 y | Retrospective | ARI/65.5 | ER,PW, PICU | RSV, Flu, PIV, AdV, HRV, hMPV | Coinfection vs single infection | NO2 and NPICU | |
| 2009 | France | 141 | 21.2 | <1 y | Prospective | Bronchiolitis/No | PW | RSV, Flu, PIV, AdV, HRV, hMPV, HCoV, EV | RSV + HRV vs RSV and HRV | LOS, LO2 and NO2 | |
| 2012 | Chile | 110 | 37.2 | <18 y | Prospective | ARI/No | PW | RSV, Flu, PIV, AdV, HRV, hMPV, HCoV, HBoV, EV | Coinfection vs single infection | LOS and LO2 | |
| 2014 | Spain | 385 | 61.8 | <15 y | Prospective | ARI/No | PW | RSV, Flu, PIV, AdV, HRV, hMPV, HCoV, HBoV, EV | Coinfection vs single infection | NO2, NPICU and NMV | |
| 2009 | Italy | 98 | 15.3 | <1 y | Prospective | Bronchiolitis/ | PW | RSV, Flu, PIV, AdV, HRV, hMPV, HCoV, HBoV | RSV + HBoV vs RSV, HRV and HBoV | LOS | |
| 2013 | Japan | 151 | 12.5 | <18 y | Prospective | ARI/Not mentioned | ER | RSV, Flu, PIV, AdV, HRV, hMPV, HBoV, EV | Coinfection vs single infection | LOS, LO2, NH and NO2 | |
| 2010 | Brazil | 72 | 47.2 | <2 y | Prospective | Bronchiolitis/19% | ER | RSV, Flu, PIV, AdV, HRV, hMPV, HCoV, HBoV, EV | Coinfection vs single infection, RSV coinfection vs RSV | NPICU and NH | |
| 2012 | Canada | 918 | 17.1 | <3 y | Prospective | ARI/14 | Out, ER, PW, PICU | RSV, Flu, PIV, AdV, HRV, hMPV, HCoV, EV | Coinfection vs single infection, RSV coinfection vs RSV, hMPV coinfection vs Hmpv | NH | |
| 2013 | Madagascar | 273 | 70.3 | <5 y | Prospective | LRTI/17.8 | ER | RSV, Flu, PIV, AdV, HRV, hMPV, HCoV, HBoV | Coinfection vs single infection | Death | |
| 2012 | Sweden | 83 | 14.4 | <17 y | Retrospective | ARI/48.5 | PW | RSV, Flu, PIV, AdV, HRV, hMPV, HCoV, HBoV, EV | Flu A (H1N1) coinfections vs Flu A (H1N1) | LOS, NPICU and Death | |
| 2008 | France | 180 | 24.4 | <1 y | Retrospective | Bronchiolitis/43.9 | PW, PICU | RSV, Flu, PIV, AdV, HRV, hMPV, HCoV, EV | Coinfection vs single infection | NPICU | |
| 2015 | USA | 511 | 12.7 | <18 y | Retrospective | ARI/26.2 | PICU | RSV, Flu, PIV, AdV, HRV, hMPV, EV | HRV coinfection vs HRV | Death | |
| 2011 | USA | 187 | 27.8 | <2 y | Prospective | ARI/17.9 | PW | RSV, Flu, PIV, AdV, HRV, hMPV, HCoV, EV | Coinfection vs single infection | LOS, NO2 and NPICU | |
| 2013 | Vietnam | 257 | 22.9 | <14 y | Prospective | ARI/No | ER | RSV, Flu, PIV, AdV, HRV, hMPV, HCoV, HBoV | RSV coinfection vs RSV | LOS | |
| 2014 | Vietnam | 78 | 66.6 | <14 y | Prospective | ARI/No | ER | RSV, Flu, PIV, AdV, HRV, hMPV, HCoV, HBoV | HBoV coinfection vs HBoV | LOS | |
| 2011 | South Africa | 510 | 54.7 | <5 y | Prospective | ARI/61.1 | ER, PW, PICU | RSV, Flu, PIV, AdV, HRV, hMPV, HCoV, HBoV | Coinfection vs single infections of RSV, PIV-3, Flu A, AdV, HRV, hMPV, HBoV, HCoV | NH, NPICU and Death | |
| 2010 | China | 69 | 46.3 | <13 y | Prospective | Pneumonia/32.3 | PW | RSV, Flu, PIV, AdV, HRV, hMPV, HCoV, HBoV, EV | RSV + HRV A vs HRV A, RSV + HRV B vs HRV B | LOS and NO2 | |
| 2010 | China | 45 | 55.5 | <14 y | Prospective | ARI/2.2 | PW | RSV, Flu, PIV, AdV, HRV, hMPV, HCoV, HBoV | hMPV coinfection vs hMPV | NH | |
| 2013 | China | 76 | 57.9 | <13 y | Prospective | LRTI/18.4 | PW | RSV, Flu, PIV, AdV, HRV, hMPV, HCoV, HBoV | hMPV vs hMPV coinfection, hMPV + HBoV and hMPV + RSV | LOS | |
| 2014 | China | 202 | 52.9 | <13 y | Prospective | LRTI/3.9 | PW | RSV, Flu, PIV, AdV, HRV, hMPV, HCoV, HBoV | HRV coinfection vs HRV | NO2 | |
| 2010 | China | 327 | 40 | <14 y | Prospective | ARI/7.9 | PW | RSV, Flu, PIV, AdV, HRV, hMPV, HCoV, HBoV | RSV coinfection vs RSV | LOS and NH | |
| 2012 | China | 129 | 37.9 | <3 y | Prospective | ARI/No | PW | RSV, Flu, PIV, AdV, HRV, hMPV, HCoV, HBoV, EV | Coinfection vs single infection | NPICU |
Abbreviations: AdV = Adenovirus, ARI = Acute respiratory infections, EV = Enterovirus, ER = Emergency room, Flu = Influenza, HBoV = Human Bocavirus, HCoV = Human Coronavirus, hMPV = Human Metapneumovirus, HRV = Human Rhinovirus, LOS = Length of stay, LO2 = Length of supplemental oxygen, LRTI = Lower respiratory tract infection, NH = Need of Hospitalization, NMV = Need of mechanical ventilation, NO2 = Need of supplemental oxygen, NPICU = Need of pediatric intensive care unit, OUT = outpatient, PIV = Parainfluenza virus, PW = Pediatric ward, RSV = Respiratory Syncytial Virus.
Summary of findings and quality of evidence for severity of viral coinfections versus single infections in children.
| Outcomes | No of Participants (studies) | Quality of the evidence | Relative effect | Anticipated absolute effects | |
|---|---|---|---|---|---|
| Risk with Single infection | Risk difference with viral coinfection (95% CI) | ||||
| 3548 (24 studies) | ⊕⊕⊕⊝ | The mean length of stay in viral coinfection group was | |||
| 2296 (7 studies) | ⊕⊝⊝⊝ | ||||
| 9637 (11 studies) | ⊕⊕⊕⊝ | ||||
| 492 (3 studies) | ⊕⊕⊝⊝ | ||||
| 674 (5 studies) | ⊕⊕⊕⊝ | The mean length of supplemental oxygen in viral coinfection group was | |||
| 2285 (12 studies) | ⊕⊕⊝⊝ | ||||
| 2630 (11 studies) | ⊕⊕⊕⊝ | ||||
Note: CI: Confidence interval; OR: Odds ratio;
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
Sixteen of twenty four included studies have no substantial risk of bias. The remaining eight have problems due to potential selection bias and/or failures to report or control of confounders.
No serious inconsistency was found.
In sixteen included studies, comparison was based upon specific viral combinations.
Optimal sample size for detecting a difference of 1 day (alpha 0.05 and power of 80%) was met and null hypothesis, which was considered the most plausible, was met.
No substantial publications bias was detected.
Four of included studies have failures to report or control of confounders.
High statistical heterogeneity (p < 0.01 and/or I2 > 50%) was found.
In four included studies, comparison was based upon all viral coinfections and all single infections.
Optimal information size was not achieved and 95% confidence interval was wide.
Eight included studies have no substantial risk of bias. The remaining three have failure to report or control of confounders.
In seven included studies, comparison was based upon all viral coinfections and all single infections.
Optimal sample size was met and 95% confidence interval was narrow and included null effect, which was considered most plausible hypothesis.
No serious risk of bias was found in most of bias domains of included studies.
In two included studies, comparison was based upon specific viral combinations.
Three included studies have a substantial risk of bias due to selection bias and/or failure to report or control of confounders.
In three included studies, comparison was based upon all viral coinfections and all single infections.
Eight studies have no substantial risk of bias. The remaining four have failure to report or control of confounders.
In half of included studies, comparison was based upon specific viral combinations.
Six included studies have no substantial risk of bias. The remaining five have failure to report or control of confounders.
In nine included studies, comparison was based upon all viral coinfections and all single infections.
Fig. 2Meta-analysis for length of stay comparing patients with viral coinfections and single infections in three age groups. Negative value indicates shorter time in patients with coinfections.
Fig. 3Meta-analysis for risk of death comparing patients with viral coinfections and single infections in three age groups. Value higher than one indicates higher risk in patients with coinfections.
Fig. 4Meta-analysis for risk of hospitalization comparing patients with viral coinfections and single infections in three age groups. Value less than one indicates less risk in patients with coinfections.
Fig. 5Meta-analysis for risk of mechanical ventilation comparing patients with viral coinfections and single infections in three age groups. Value less than one indicates less risk in patients with coinfections.